Newly Confident Hutchmed Weans Itself from Partners, Prepares to Stand on Its Own
Oncological drug specialist backed by billionaire Li Ka-shing sells OTC business and raises $200 million, half from Baring Private Equity Asia Key Takeaways Hutchmed predicts revenue from its core oncology…
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
Sales success comes with side effects for drug maker BeiGene
BGNE.US 6160.HK
-
CStone breaks up with drugs partner as U.S. rollout stalls
2616.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
BeiGene goes for global growth with sales and R&D push
BGNE.US 6160.HK
Discover hidden China stock gems in our weekly newsletter